H00006690-M01

Lu Z, Williamson SR, Carskadon S, Arachchige PD, Dhamdhere G, Schultz DS, Stricker H, Peabody JO, Jeong W, Chitale DA, Bismar TA, Rogers CG, Menon M, Gupta NS, Palanisamy N
The Prostate 2020 Jan;80(1):38-50

Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.

Tiwari R, Manzar N, Bhatia V, Yadav A, Nengroo MA, Datta D, Carskadon S, Gupta N, Sigouros M, Khani F, Poutanen M, Zoubeidi A, Beltran H, Palanisamy N, Ateeq B
Nature communications 2020 Jan 20;11(1):384

Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.

Koide H, Kimura T, Inaba H, Sato S, Iwatani K, Yorozu T, Furusato B, Kamata Y, Miki J, Kiyota H, Takahashi H, Egawa S
The Prostate 2019 Jan;79(1):3-8

SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.

Faisal FA, Kaur HB, Tosoian JJ, Tomlins SA, Schaeffer EM, Lotan TL
Prostate cancer and prostatic diseases 2019 Dec;22(4):552-559

Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate.

Patil PA, McKenney JK, Reynolds JP, Przybycin CG, Magi-Galluzzi C
Histology and histopathology 2019 Apr;34(4):381-390

Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity.

Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstråhle J, Tarish F, Tanoglidi A, Vickovic S, Larsson L, Salmén F, Ogris C, Wallenborg K, Lagergren J, Ståhl P, Sonnhammer E, Helleday T, Lundeberg J
Nature communications 2018 Jun 20;9(1):2419

Ductal adenocarcinoma of the prostate: Clinical and biological profiles.

Vinceneux A, Bruyère F, Haillot O, Charles T, de la Taille A, Salomon L, Allory Y, Ouzaid I, Choudat L, Rouprêt M, Comperat E, Houede N, Beauval JB, Vourc'h P, Fromont G
The Prostate 2017 Sep;77(12):1242-1250

Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.

Shek FH, Luo R, Lam BYH, Sung WK, Lam TW, Luk JM, Leung MS, Chan KT, Wang HK, Chan CM, Poon RT, Lee NP
Cellular oncology (Dordrecht) 2017 Oct;40(5):443-456

Novel method to rescue a lethal phenotype through integration of target gene onto the X-chromosome.

Sakata K, Araki K, Nakano H, Nishina T, Komazawa-Sakon S, Murai S, Lee GE, Hashimoto D, Suzuki C, Uchiyama Y, Notohara K, Gukovskaya AS, Gukovsky I, Yamamura KI, Baba H, Ohmuraya M
Scientific reports 2016 Nov 15;6:37200

The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line.

Zhang J, Wang D, Hu N, Wang Q, Yu S, Wang J
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 May;37(5):5847-55

Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.

Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK
PloS one 2015;10(7):e0132343

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES
Oncotarget 2015 Nov 3;6(34):35737-54

Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.

Palanisamy N, Tsodikov A, Yan W, Suleman K, Rittmaster R, Lucia SM, Chinnaiyan AM, Fleshner N, Kunju LP
Urologic oncology 2015 Mar;33(3):108.e5-13

Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.

Ateeq B, Kunju LP, Carskadon SL, Pandey SK, Singh G, Pradeep I, Tandon V, Singhai A, Goel A, Amit S, Agarwal A, Dinda AK, Seth A, Tsodikov A, Chinnaiyan AM, Palanisamy N
The Prostate 2015 Jul 1;75(10):1051-62

SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression.

Tiwari R, Pandey SK, Goel S, Bhatia V, Shukla S, Jing X, Dhanasekaran SM, Ateeq B
Oncogenesis 2015 Aug 10;4(8):e162

SPINK1 protein expression and prostate cancer progression.

Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Sep 15;20(18):4904-11

Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, Kunju LP, Cooney KA, Tomlins SA
The American journal of surgical pathology 2014 May;38(5):615-26

Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker.

Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT
PloS one 2013;8(3):e59459

Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.

Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM
Urologic oncology 2013 Nov;31(8):1716-24

Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.

Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Mosquera JM, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013 Jun;26(6):835-48

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009 Sep;22(9):1176-85

The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM
Cancer cell 2008 Jun;13(6):519-28

No comments: Submit comment

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Western Blot: SPINK1 Antibody (4D4) [H00006690-M01] - SPINK1 monoclonal antibody (M01), clone 4D4. Analysis of SPINK1 expression in human pancreas.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Western Blot: SPINK1 Antibody (4D4) [H00006690-M01] - detection against Immunogen (31.9 KDa) .Antibody reactive against recombinant protein.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: ELISA: SPINK1 Antibody (4D4) [H00006690-M01] - Detection limit for recombinant GST tagged SPINK1 is 0.03 ng/ml as a capture antibody.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Immunoprecipitation: SPINK1 Antibody (4D4) [H00006690-M01] - Analysis of SPINK1 transfected lysate using anti-SPINK1 monoclonal antibody and Protein A Magnetic Bead, and immunoblotted with SPINK1 MaxPab rabbit polyclonal antibody.

Supportive validation

Submitted by: Novus Biologicals (provider)
Main image
Experimental details: Immunohistochemistry-Paraffin: SPINK1 Antibody (4D4) [H00006690-M01] - Analysis of monoclonal antibody to SPINK1 on formalin-fixed paraffin-embedded human pancreas. Antibody concentration 1 ug/ml.